InspireMD Gains Commercialization Approval in Russia for CGuard

November 14, 2016

InspireMD has received regulatory approval to commercialize the CGuard Embolic Prevention System (EPS) for the treatment of carotid artery disease in Russia.

The CGuard EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining perfusion to the external carotid artery.

CGuard EPS is CE Marked and not approved for sale in the U.S. by the FDA at this time. — Cynthia Jessup

View today's stories